The global Nuclear Receptor ROR Gamma market is valued at million US$ in 2018 is expected to reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
This report focuses on Nuclear Receptor ROR Gamma volume and value at global level, regional level and company level. From a global perspective, this report represents overall Nuclear Receptor ROR Gamma market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Genfit SA
GlaxoSmithKline Plc
Aurigene Discovery Technologies Ltd
Beijing Hanmi Pharmaceutical Co Ltd
Biogen Inc
AbbVie Inc
Advinus Therapeutics Ltd
Brickell Biotech Inc
Pfizer Inc
Phenex Pharmaceuticals AG
Reata Pharmaceuticals Inc
Bristol-Myers Squibb Company
Celgene Corp
Eli Lilly and Company
Glenmark Pharmaceuticals Ltd
Lead Pharma Holding BV

Segment by Regions
North America
Europe
China
Japan

Segment by Type
BBI-6000
GRC-39815Action
R&D Progress
GSK-2981278
IMU-366
INV-17
Others

Segment by Application
Chronic Obstructive Pulmonary Disease
Asthma
Axial Spondyloarthritis
Breast Cancer
Others